Secarna Pharmaceuticals GmbH & Co. KG a biopharmaceutical company focusing on the discovery and development of next generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAplus TM platform, announced today that the Company has appointed Alexander Gebauer, MD, PhD as CEO and Managing Director.
February 4, 2021
· 4 min read